LABORIE completed its acquisition of Mediwatch Plc, a manufacturer and distributor of Urology and GI diagnostic products, including Urodynamics systems and disposables, bladder scanners, uroflowmeters, Pelvic Floor Biofeedback equipment, Anorectal Manometry systems and PSA Test equipment and disposables. The transaction was effective as of January 27, 2014.
“This acquisition further strengthens our foundation in Pelvic Muscle Rehabilitation and GI diagnostics by combining two market leaders in Urology and GI diagnostic products” stated Brian Ellacott, LABORIE President and CEO. “The combined resources of Mediwatch Plc. and LABORIE will allow us to accelerate our investments in development of innovative products, provide more comprehensive sales and customer service, as well as provide superior after-sales service to all of our global customers.”
Investec Bank plc and Raymond James & Associates, Inc., served as financial advisors to LABORIE. DWF LLP and Kirkland & Ellis LLP served as legal advisor.
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Clinical Innovations for an enterprise value of $525 million.
LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”).
LABORIE Medical Technologies (“LABORIE”) announced the successful completion of the tender offer by its affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”) to purchase all outstanding shares of common stock of Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”)